Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Berubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : CNS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : For the large scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
January 14, 2020
Lead Product(s) : Berubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : CNS Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
